{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:12:22Z","timestamp":1788232342500,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022599","name":"Korea Hydro and Nuclear Power Central Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.intimp.2024.112884","type":"journal-article","created":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T11:20:22Z","timestamp":1723375222000},"page":"112884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["SPH7854, a gut-limited ROR\u03b3t antagonist, ameliorates TNBS-induced experimental colitis in rat"],"prefix":"10.1016","volume":"140","author":[{"given":"Zhijun","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehua","family":"huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-353X","authenticated-orcid":false,"given":"Guangxin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112884_b0005","unstructured":"L.M. Genaro et al. Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach, Am. J. Transl. Res. 13(12) (2021) (1943-8141\/AJTR0138856) 13916-13930."},{"issue":"12","key":"10.1016\/j.intimp.2024.112884_b0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2024.112884_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent advances in the treatment of IBD: Targets, mechanisms and related therapies","volume":"71\u201372","author":"Liu","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20072713","article-title":"Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22","volume":"206","author":"Takatori","year":"2009","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0030","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112884_b0035","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00296-011-1995-7","article-title":"Evaluation of the T helper 17 axis in ankylosing spondylitis","volume":"32","author":"Taylan","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"9","key":"10.1016\/j.intimp.2024.112884_b0040","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/gut.2007.130112","article-title":"The role of the novel Th17 cytokine IL-26 in intestinal inflammation","volume":"58","author":"Dambacher","year":"2009","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.intimp.2024.112884_b0050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00011-014-0768-7","article-title":"Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease","volume":"63","author":"Jiang","year":"2014","journal-title":"Inflamm. Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112884_b0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ibd.20339","article-title":"Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD","volume":"14","author":"Seiderer","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.112884_b0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.4046","article-title":"Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells","volume":"22","author":"Withers","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.112884_b0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bcp.2018.01.023","article-title":"Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORgammat inverse agonist","volume":"150","author":"Shibata","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112884_b0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10787-019-00643-z","article-title":"VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease","volume":"28","author":"Fitzpatrick","year":"2020","journal-title":"Inflammopharmacology"},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2016.1153066","article-title":"Retinoid-related orphan receptor gamma t (RORgammat) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742","volume":"26","author":"Gege","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"issue":"11","key":"10.1016\/j.intimp.2024.112884_b0080","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.autrev.2016.07.036","article-title":"Retinoid-related orphan receptor gamma (RORgamma) adult induced knockout mice develop lymphoblastic lymphoma","volume":"15","author":"Liljevald","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2024.112884_b0085","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/ibd\/izy167","article-title":"Activation of LANCL2 by BT-11 ameliorates IBD by supporting regulatory T cell stability through immunometabolic mechanisms","volume":"24","author":"Leber","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.112884_b0090","doi-asserted-by":"crossref","first-page":"1083333","DOI":"10.3389\/fimmu.2023.1083333","article-title":"A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans","volume":"14","author":"Dodd","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112884_b0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/acsmedchemlett.3c00001","article-title":"Trust your gut: strategies and tactics for intestinally restricted drugs","volume":"14","author":"Dorel","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0100","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.jmedchem.9b01439","article-title":"Discovery of a gut-restricted JAK inhibitor for the treatment of inflammatory bowel disease","volume":"63","author":"Leonard","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2024.112884_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112536","article-title":"Discovery of carboxyl-containing biaryl ureas as potent ROR\u03b3t inverse agonists","volume":"202","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.intimp.2024.112884_b0110","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/ibd.22897","article-title":"Magnetic resonance colonography in rats with TNBS-induced colitis: A feasibility and validation study","volume":"18","author":"Charpentier","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"issue":"10","key":"10.1016\/j.intimp.2024.112884_b0115","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3748\/wjg.v11.i10.1508","article-title":"Activation of nuclear factor-kappa B and effects of pyrrolidine dithiocarbamate on TNBS-induced rat colitis","volume":"11","author":"Ken Chen","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112884_b0120","article-title":"Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis","volume":"10","author":"Camussi","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.intimp.2024.112884_b0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10620-010-1286-2","article-title":"CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model","volume":"56","author":"Ogino","year":"2011","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0130","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1172\/JCI78089","article-title":"T cells in the control of organ-specific autoimmunity","volume":"125","author":"Bluestone","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.intimp.2024.112884_b0135","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.4049\/jimmunol.0903243","article-title":"RORC2 is involved in T cell polarization through interaction with the FOXP3 promoter","volume":"184","author":"Burgler","year":"2010","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112884_b0140","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/cb3002649","article-title":"Identification of a selective RORgamma ligand that suppresses T(H)17 cells and stimulates T regulatory cells","volume":"7","author":"Solt","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.intimp.2024.112884_b0145","first-page":"901","article-title":"High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor RORgamma","volume":"62","author":"Eiichiro Ueda","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0150","first-page":"93","article-title":"Thymic lymphomas in a 6-month rasH2-Tg mouse carcinogenicity study with the RORgammat inverse agonist, BMS-986251","volume":"183","author":"Haggerty","year":"2021","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.intimp.2024.112884_b0155","doi-asserted-by":"crossref","first-page":"e003","DOI":"10.1621\/nrs.07003","article-title":"Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism","volume":"7","author":"Jetten","year":"2009","journal-title":"Nucl. Recept. Signal."},{"issue":"2","key":"10.1016\/j.intimp.2024.112884_b0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1152\/physiolgenomics.00098.2007","article-title":"Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism","volume":"31","author":"Kang","year":"2007","journal-title":"Physiol. Genomics"},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/me.2012-1145","article-title":"Regulation of the human hydroxysteroid sulfotransferase (SULT2A1) by RORalpha and RORgamma and its potential relevance to human liver diseases","volume":"27","author":"Ou","year":"2013","journal-title":"Mol. Endocrinol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112884_b0170","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/17460441.2021.1948833","article-title":"Retinoic acid-related orphan receptor gamma t (RORgammat) inverse agonists\/antagonists for the treatment of inflammatory diseases - where are we presently?","volume":"16","author":"Gege","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/gut.32.1.50","article-title":"5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease","volume":"32","author":"Mahida","year":"1991","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.intimp.2024.112884_b0180","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/0016-5085(90)90329-Y","article-title":"Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid","volume":"98","author":"Ahnfelt-R\u00f8nne","year":"1990","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112884_b0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2036.1988.tb00689.x","article-title":"Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid","volume":"2","author":"Nielsen","year":"1988","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2024.112884_b0190","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1365-2036.2011.04619.x","article-title":"Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis","volume":"33","author":"Harris","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0195","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112884_b0200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CEG.S293272","article-title":"Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives","volume":"14","author":"Gubatan","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11938-018-0175-1","article-title":"Novel therapies and treatment strategies for patients with inflammatory bowel disease","volume":"16","author":"Duijvestein","year":"2018","journal-title":"Curr. Treat Options Gastroenterol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112884_b0210","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/cpdd.946","article-title":"Single- and multiple-dose pharmacokinetics and pharmacodynamics of PN-943, a Gastrointestinal-restricted oral peptide antagonist of alpha4beta7, in healthy volunteers","volume":"10","author":"Modi","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0215","doi-asserted-by":"crossref","first-page":"e12842","DOI":"10.1111\/sji.12842","article-title":"Upregulated IL-17A secretion and CCR6 co-expression in Treg subsets are related to the imbalance of Treg\/Th17 cells in active UC patients","volume":"91","author":"Long","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2024.112884_b0220","doi-asserted-by":"crossref","first-page":"1028899","DOI":"10.3389\/fcimb.2022.1028899","article-title":"Protective effect of Schistosoma japonicum eggs on TNBS-induced colitis is associated with regulating Treg\/Th17 balance and reprogramming glycolipid metabolism in mice","volume":"12","author":"Hou","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"29","key":"10.1016\/j.intimp.2024.112884_b0225","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.3748\/wjg.v19.i29.4702","article-title":"Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses","volume":"19","author":"Chen","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2024.112884_b0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cyto.2017.01.008","article-title":"Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens","volume":"92","author":"Velikova","year":"2017","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.intimp.2024.112884_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/biom10070974","article-title":"Transcriptome based profiling of the immune cell gene signature in rat experimental colitis and human IBD tissue samples","volume":"10","author":"Boros","year":"2020","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.intimp.2024.112884_b0240","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/eji.1830270722","article-title":"Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice","volume":"27","author":"Neurath","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2024.112884_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.746725","article-title":"Photodynamic therapy of novel photosensitizer ameliorates TNBS-induced ulcerative colitis via inhibition of AOC(1)","volume":"12","author":"Rong","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112884_b0250","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.4049\/jimmunol.181.9.5948","article-title":"IL-23 promotes maintenance but not commitment to the Th17 lineage","volume":"181","author":"Stritesky","year":"2008","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112884_b0255","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40265-023-01882-9","article-title":"Targeting IL-23 for IBD: rationale and progress to date","volume":"83","author":"Vuyyuru","year":"2023","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0260","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0016-5085(00)70351-9","article-title":"Claudins regulate the intestinal barrier in response__to immune mediators","volume":"118","author":"Kinugasa","year":"2000","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.intimp.2024.112884_b0265","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.intimp.2024.112884_b0270","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.intimp.2024.112884_b0275","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112884_b0280","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.112884_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02307","article-title":"An ROR\u03b3t oral inhibitor modulates IL-17 responses in peripheral blood and intestinal mucosa of Crohn's disease patients","volume":"9","author":"Bassolas-Molina","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0290","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0295","doi-asserted-by":"crossref","first-page":"e54543","DOI":"10.1371\/journal.pone.0054543","article-title":"Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD","volume":"8","author":"Brenna","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2024.112884_b0300","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1006\/clim.2001.5134","article-title":"Animal models of human disease: experimental autoimmune gastritis\u2013a model for autoimmune gastritis and pernicious anemia","volume":"102","author":"Alderuccio","year":"2002","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112884_b0305","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/17460441.2021.1851185","article-title":"Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis","volume":"16","author":"Bilsborough","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"issue":"2","key":"10.1016\/j.intimp.2024.112884_b0310","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn's disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis. Mon."},{"issue":"12","key":"10.1016\/j.intimp.2024.112884_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692401405X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692401405X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:04:30Z","timestamp":1786363470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692401405X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":63,"alternative-id":["S156757692401405X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112884","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SPH7854, a gut-limited ROR\u03b3t antagonist, ameliorates TNBS-induced experimental colitis in rat","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112884"}}